Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-01-08
2008-01-08
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S196000
Reexamination Certificate
active
10728340
ABSTRACT:
The invention is directed to compositions used for treating Central Nervous System (CNS) disorders. More specifically, the invention is directed to derivatized, e.g., ester or carboxylic acid derivatized, doxepins, and analogs thereof, useful for the treatment of sleep disorders.
REFERENCES:
patent: 4383999 (1983-05-01), Bondinell et al.
patent: 4514414 (1985-04-01), Bondinell et al.
patent: 4610995 (1986-09-01), Coker et al.
patent: 4929618 (1990-05-01), Koda et al.
patent: 4931450 (1990-06-01), Sonnewald
patent: 5095022 (1992-03-01), Ito et al.
patent: 5153207 (1992-10-01), Ito et al.
patent: 5225559 (1993-07-01), Kita et al.
patent: 5231105 (1993-07-01), Shoji et al.
patent: 5250681 (1993-10-01), Shoji et al.
patent: 5393890 (1995-02-01), Syoji et al.
patent: 5801175 (1998-09-01), Afonso et al.
patent: 6054458 (2000-04-01), Jørgensen et al.
patent: 6174898 (2001-01-01), Weis et al.
patent: 6191165 (2001-02-01), Ognyanov et al.
patent: 6214827 (2001-04-01), Afonso et al.
patent: 6288083 (2001-09-01), Luly et al.
patent: 6288084 (2001-09-01), Luly et al.
patent: 6307052 (2001-10-01), Kita et al.
patent: 6358944 (2002-03-01), Lederman et al.
patent: 6387930 (2002-05-01), Baroudy et al.
patent: 6391890 (2002-05-01), Jorgensen et al.
patent: 6503926 (2003-01-01), Luly et al.
patent: RE38257 (2003-09-01), Shoji et al.
patent: 0 335 586 (1989-10-01), None
patent: 0 399 414 (1990-11-01), None
patent: 0 406 739 (1991-01-01), None
patent: 0 949 260 (1999-10-01), None
patent: 03133956 (1991-06-01), None
patent: 05-17442 (1993-01-01), None
patent: 05-17443 (1993-01-01), None
patent: 05-294929 (1993-11-01), None
patent: 2001-261553 (2001-09-01), None
patent: 2004-051600 (2004-02-01), None
patent: WO88/09656 (1988-12-01), None
patent: WO95/01350 (1995-01-01), None
patent: WO96/31478 (1996-10-01), None
patent: WO97/45115 (1997-12-01), None
patent: WO99/00376 (1999-01-01), None
patent: WO 00/14064 (2000-03-01), None
patent: WO 03/033489 (2003-04-01), None
Timmerman et al. “Preparation of piperidine . . . ” CA 126:18791 (1996).
Iwasaki, N., et al., “Amphoteric Drugs. II.1)Synthesis and Antiallergic Activity of [4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)piperidino]alkanoic Acid Derivatives and Related Compounds,”Chem Pharm Bull, 42(11):2285-2290 (1994).
Iwasaki, et al., “Amphoteric drugs. I. Synthesis and antiallergic activity of [4- (diphenylmethoxy) piperidino]-, [4- (diphenylmethyl) piperazinyl]- and [4- (diphenylmethylene) piperidino] alkanoic acid derivatives,”Chemical&Pharmaceutical Bulletin, 42(11):2276-2284 (1994). Abstract Accession #: 1995: 441018 HCAPLUS.
Iwasaki, N., et al., “Amphoteric Drugs. I. Synthesis and Antiallergic Activity of [4-(Diphenylmethoxy)piperidino]-, [4(Diphenylmethyl)piperazinyl]- and [4-(Diphenylmethylene)piperidino]alkanoic Acid Derivatives,”Chem. Pharm. Bull., 42(11): 2276-2284 (1994).
Andersen et al.J. Med. Chem., 36(12):1716-1725 (1993).
Andersen et al.J. Med. Chem., 42:4281-4291 (1999).
Dhar et al.Bioorg. Med. Chem. Lett., 6(13):1535-1540 (1996).
Falch et al.Eur. J. Med. Chem., 26:69-78 (1991).
Iwasaki et al.Chem. Pharm. Bull., 42(11):2276-2284 (1994).
Iwasaki et al.Chem. Pharm. Bull., 42(11):2285-2290 (1994).
Muramatsu et al.Chem. Pharm. Bull., 41(11)1987-1993 (1993).
N'Goka et al.J. Med. Chem., 34(8):2547-2557 (1991).
Ohshima et al.J. Med. Chem., 35(11):2074-2084 (1992).
Patani et al.Chem. Rev., 96(8):3147-3176 (1996).
Yunger et al.J. Pharmacol. Exp. Ther., 228(1):109-115 (1984).
Hajak et al., “Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study”,J. Clin. Psychiatry, 62:453-463 (2001).
Edgar Dale M.
Hangauer David G.
Leighton Harry Jefferson
Mignot Emmanuel J. M.
Chang Celia
Elrifi Ivor R.
Erlacher Heidi A.
Hypnion, Inc.
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
LandOfFree
CNS target modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CNS target modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CNS target modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3926835